|
 |
|
|||||||
|
|||||||||
Copyright © ERS Journals Ltd 1994
Clinical Trial |
High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects
Atrial natriuretic peptide (ANP) has been shown to be an effective bronchodilator when given intravenously, but its efficacy by inhalation has not been assessed. In the first part of the current study, six asthmatic subjects, mean (SEM) forced expiratory volume in one second (FEV1) 2.09 (0.30) l, received 0.1 and 1 mg atrial natriuretic peptide by inhalation, and in the second study five subjects, FEV1 1.92 (0.40) l, received 5 mg ANP by inhalation. ANP was given in a placebo-controlled, double blind, randomized manner, with measurement of FEV1 over the following 60 min. Nebulized salbutamol was given at 60 min as a measure of the maximal bronchodilator response attainable by conventional therapy. No significant bronchodilator effect was seen following the 0.1 or 1 mg inhalation, although the latter produced a minimal transient elevation in peripheral atrial natriuretic peptide plasma levels. A bronchodilator effect was seen with the 5 mg dose, which produced delta FEV1 0.42 (0.09) l compared to 0.93 (0.13) l subsequently produced by salbutamol. This effect peaked at 5 min and was no different from placebo from 10 min onwards. We conclude that atrial natriuretic peptide may produce significant bronchodilation when given by inhalation in high doses, and speculate that substances which generate cyclic guanosine monophosphate (cGMP) in airway smooth muscle warrant further investigation as potential bronchodilatory agents.
This article has been cited by other articles:
|
|
 |
|
  M. J. Akerman, M. Yaegashi, Z. Khiangte, A. T. Murugan, O. Abe, and J. D. Marmur Bronchodilator effect of infused B-type natriuretic Peptide in asthma. Chest, July 1, 2006; 130(1): 66 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Hamad, A. Clayton, B. Islam, and A. J. Knox Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function Am J Physiol Lung Cell Mol Physiol, November 1, 2003; 285(5): L973 - L983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Rho, W. J. Perkins, R. R. Lorenz, D. O. Warner, and K. A. Jones Differential effects of soluble and particulate guanylyl cyclase on Ca2+ sensitivity in airway smooth muscle J Appl Physiol, January 1, 2002; 92(1): 257 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hamad, S. R. Johnson, and A. J. Knox Antiproliferative effects of NO and ANP in cultured human airway smooth muscle Am J Physiol Lung Cell Mol Physiol, November 1, 1999; 277(5): L910 - L918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Hamad, S. P. Range, E. Holland, and A. J. Knox Desensitization of Guanylyl Cyclases in Cultured Human Airway Smooth-Muscle Cells Am. J. Respir. Cell Mol. Biol., May 1, 1999; 20(5): 1087 - 1095. [Abstract] [Full Text]
|
|
|
|
|
|
A. M. Hamad, S. Range, E. Holland, and A. J. Knox Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle Am J Physiol Lung Cell Mol Physiol, October 1, 1997; 273(4): L807 - L813. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |